From here to epilepsy: The risk of seizure in patients with Alzheimer's disease

Epileptic Disorders

Volumn 18, Issue 1, 2016, Pages 1-12

  Nicastro, Nicolas ^a   Assal, Frédéric ^a   Seeck, Margitta ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Alzheimer's disease; Epilepsy; Major neurocognitive disorder; Seizure

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PRESENILIN 1; PRESENILIN 2; VALPROIC ACID;

ALZHEIMER DISEASE; ASTHENIA; ATAXIA; CONFUSION; CORTICAL EXCITABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOWN SYNDROME; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EEG ABNORMALITY; EPILEPSY; HEADACHE; HUMAN; INCIDENCE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; MOUSE MODEL; MYOCLONUS EPILEPSY; NERVE DEGENERATION; NERVE EXCITABILITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEIZURE; SOMNOLENCE; TEMPORAL LOBE EPILEPSY; TRANSIENT EPILEPTIC AMNESIA; ANIMAL; COMPLICATION; DISEASE MODEL; METABOLISM; RISK; SEIZURES;

ALZHEIMER DISEASE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; RISK; SEIZURES;

EID: 84961712021     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2016.0808     Document Type: Review

References (73)

1. Abraham H, Veszpremi B, Kravjak A, Kovacs K, Gomori E, Seress L. Ontogeny of calbindin immunoreactivity in the human hippocampal formation with a special emphasis on granule cells of the dentate gyrus. Int J Dev Neurosci 2009; 27: 115-27.
2. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006; 47: 867-72.
3. Arroyo S, Kramer G. Treating epilepsy in the elderly: Safety considerations. Drug Saf 2001; 24: 991-1015.
4. Bartfai T, Sanchez-Alavez M, Andell-Jonsson S, et al. Interleukin-1 system in CNS stress: Seizures, fever, and neurotrauma. Ann N Y Acad Sci 2007; 1113: 173-7.
5. Belcastro V, Costa C, Galletti F, Pisani F, Calabresi P, Parnetti L. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: A prospective observational study. Eur J Neurol 2007; 14: 1176-8.
6. Bell JS, Lönnroos E, Koivisto AM, et al. Use of antiepileptic drugs among community-dwelling persons with Alzheimer's disease in Finland. J Alzheimers Dis 2011; 26: 231-7.
7. Bernardi S, Scaldaferri N, Vanacore N, et al. Seizures in Alzheimer'sdisease: A retrospective study of a cohort of outpatients. Epileptic Disord 2010; 12: 16-21.
8. Born HA, Kim JY, Savjani RR, et al. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci 2014; 34: 3826-40.
9. Butler CR, Zeman AZ. Recent insights into the impairment of memory in epilepsy: Transient epileptic amnesia, accelerated long-Term forgetting and remote memory impairment. Brain 2008; 131: 2243-63.
10. Butler C, van Erp W, Bhaduri A, Hammers A, Heckemann R, Zeman A. Magnetic resonance volumetry reveals focal brain atrophy in transient epileptic amnesia. Epilepsy Behav 2013; 28: 363-9.
11. Cabrejo L, Guyant-Marechal L, Laquerriere A, et al. Phenotype associated with APP duplication in five families. Brain 2006; 129: 2966-76.
12. Cheng CH, Liu CJ, Ou SM, et al. Incidence and risk of seizures in Alzheimer's disease: A nationwide populationbased cohort study. Epilepsy Res 2015; 115: 63-6.
13. Chin J. Selecting a mouse model of Alzheimer's disease. Methods Mol Biol 2011; 670: 69-89.
14. Chin J, Palop JJ, Puolivali J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2005; 25: 9694-703.
15. Cloyd J, Hauser W, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 2006; 68: S39-48.
16. Cook M, Baker N, Lanes S, Bullock R, Wentworth C, Arrighi HM. Incidence of stroke and seizure in Alzheimer's disease dementia. Age Ageing 2015; 44: 695-9.
17. Cretin B, Blanc F, Gaultier C, Sellal F. Epileptic amnesic syndrome revealing Alzheimer's disease. Epilepsy Res 2012; 102: 206-9.
18. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav 2010; 17: 461-6.
19. D'Orsi G, Specchio LM. Progressive myoclonus epilepsy in Down Syndrome patients with dementia. J Neurol 2014; 261: 1584-97.
20. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDSADRDA criteria. Lancet Neurol 2007; 6: 734-46.
21. Ezquerra M, Carnero C, Blesa R, Gelpì JL, Ballesta F, Oliva R. A presenilin 1 mutation (Ser169pro) associated with early-onset AD and myoclonic seizures. Neurology 1999; 52: 566-70.
22. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia 2014; 55: 475-82.
23. Forstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P. Neurologic signs in Alzheimer's disease. Results of a prospective clinical and neuropathologic study. Arch Neurol 1992; 49: 1038-42.
24. Fox NC, Kennedy AM, Harvey RJ, et al. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 1997; 120: 491-501.
25. Garcia-Cabrero AM, Guerrero-Lopez R, Giraldez BG, et al. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis 2013; 58: 200-8.
26. Greenberg SM, Rapalino O, Frosch MP. Case records of the Massachusetts General Hospital. Case 22-2010. An 87-year-old woman with dementia and a seizure. N Engl J Med 2010; 363: 373-81.
27. Guo Q, Furukawa K, Sopher BL, et al. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport 1996; 8: 379-83.
28. HauserWA,Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986; 36: 1226-30.
29. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester. Minnesota. Mayo Clin Proc 1996; 71: 576-86.
30. Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727-30.
31. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Early-onset Alzheimer's disease: Clinical predictors of institutionalization and death. Neurology 1987; 37: 980-4.
32. Iacopino AM, Christakos S. Specific reduction of calciumbinding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 1990; 87: 4078-82.
33. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Seizures in patients with Alzheimer's disease or vascular dementia: A population-based nested case-control analysis. Epilepsia 2013; 54: 700-7.
34. Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 368-72.
35. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989; 46: 849-53.
36. Larner AJ. Presenilin-1 mutation Alzheimer's disease: A genetic epilepsy syndrome? Epilepsy Behav 2011; 21: 20-2.
37. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 2006; 253: 139-58.
38. Letemendia F, Pampiglione G. Clinical and electroencephalographic observations in Alzheimer's disease. J Neurochem 1958; 21: 167-72.
39. Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YA, Scheltens P. Prevalence and clinical significance of epileptiform EEG discharges in a largememory clinic cohort. Dement Geriatr Cogn Disord 2010; 29: 432-7.
40. Lott IT, Doran E, Nguyen VQ, Tournay A, Movsesyan N, Gillen DL. Down syndrome and dementia: Seizures and cognitive decline. J Alzheimers Dis 2012; 29: 177-85.
41. Lozsadi DA, Larner AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 22: 121-4.
42. McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia 1992; 33: 657-60.
43. Mendez MF, Catanzaro P, Doss RC, R. AR, Frey WH. Seizures in Alzheimer's disease: Clinicopathologic study. J Geriatr Psychiatry Neurol 1994; 7: 230-3.
44. Menéndez M. Down syndrome. Alzheimer's disease and seizures. Brain Dev 2005; 27: 246-52.
45. Minkeviciene R, Rheims S, Dobszay MB, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 2009; 29: 3453-62.
46. Nicastro N, Picard F, Assal F. Transient global amnesia mimics: Transient epileptic amnesia. Epilepsy Behav Case Rep 2014; 2: 100-1.
47. Noebels JL. A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 2011; 52: 39-46.
48. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009; 66: 435-40.
49. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007; 55: 697-711.
50. Perkins ND. Integrating cell-signalling pathways with NFkappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
51. Picco A, Archetti S, Ferrara M, et al. Seizures can precede cognitive symptoms in late-onset Alzheimer's disease. J Alzheimers Dis 2011; 27: 737-42.
52. Rabinowicz AL, Starkstein SE, Leiguarda RC, Coleman AE. Transient epileptic amnesia in dementia: A treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord 2000; 14: 231-3.
53. Rao SC,DoveG, CascinoGD,Petersen RC. Recurrent seizures in patients with dementia: Frequency, seizure types, and treatment outcome. Epilepsy Behav 2009; 14: 118-20.
54. Ravizza T, Vezzani A. Status epilepticus induces timedependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. Neuroscience 2006; 137: 301-8.
55. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-52.
56. Risse SC, Lampe TH, Bird TD, et al. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis Assoc Disord 1990; 4: 217-25.
57. Roberson ED, Halabisky B, Yoo JW, et al. Amyloidbeta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neuroscience 2011a; 31: 700-11.
58. Roberson ED, Hope OA, Martin RC, Schmidt D. Geriatric epilepsy: Research and clinical directions for the future. Epilepsy Behav 2011b; 22: 103-11.
59. Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990; 47: 847-50.
60. Rossi C, De Herdt V, Dequatre-Ponchelle N, Hénon H, Leys D, Cordonnier C. Incidence and predictors of late seizures in intracerebral hemorrhages. Stroke 2013; 44: 1723-5.
61. Saetre E, Perucca A, Isojärvi J, Gjerstad L, & LAM 40089 Study Group. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292-302.
62. Samson WN, van Duijn CM, Hop WC, Hofman A. Clinical features and mortality in patients with early-onset Alzheimer's disease. Eur Neurol 1996; 36: 103-6.
63. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012; 109: E2895-903.
64. Santos SF, Pierrot N, Morel N, Gailly P, Sindic C, Octave JN. Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J Neurosci 2009; 29: 4708-18.
65. Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: Who, when, and how common? Arch Neurol 2009; 66: 992-7.
66. Sherzai D, Losey T, Vega S, Sherzai A. Seizures and dementia in the elderly: Nationwide Inpatient Sample 1999-2008. Epilepsy Behav 2014; 36: 53-6.
67. Sjogren T, Sjogren H, Lindgren AG. Morbus Alzheimer and morbus Pick; A genetic, clinical and patho-Anatomical study. Acta Psychiatr Neurol Scand Suppl 1952; 82: 1-152.
68. Stefanits H, Wesseling C, Kovacs GG. Loss of calbindin immunoreactivity in the dentate gyrus distinguishes Alzheimer's disease from other neurodegenerative dementias. Neurosci Lett 2014; 566: 137-41.
69. Sulkava R. Alzheimer's disease and senile dementia of Alzheimer type. A comparative study. Acta Neurol Scand 1982; 65: 636-50.
70. Tamagnini F, Scullion S, Brown JT, Randall AD. Intrinsic excitability changes induced by acute treatment of hippocampal CA1 pyramidal neurons with exogenous amyloid beta peptide. Hippocampus 2015; 25: 786-97.
71. Volicer L, Smith S,Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995; 6: 258-63.
72. Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 2013; 70: 1158-66.
73. Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of anti-epileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015; 56: 450-9.